CompletedNCT05320991
Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers
A short description of this study’s research objective has not yet been verified.
Medication studyAges 18–35GermanySchizophrenia
Understand this study
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
- Listed locations
- Bonn, GermanySee all locations and recruitment
- Activities
- Medication described in the protocol · Placebo comparator
- Compensation
- Payment and expense reimbursement have not been verified.
Registry last updated: · Record retrieved: . These dates do not confirm site availability.
Study information
Study start dateStarted: June 15, 2019
- Recruitment status
- Completed
- Enrollment listed in the registry
- 70
- Sponsor
- University Hospital, Bonn
- Sponsor type
- Hospital / academic medical center
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
- Locations
- Germany
- Age range
- From 18 Years to 35 Years
- Official registry ID
- NCT05320991
- Official title
- A Randomized Control Trial Employing fMRI to Investigate the Effects of Ketamine on Mentalizing and Metacognition in Healthy Volunteers
Recruitment & locations
CompletedBonn
Questions about this study
Who is behind this study?
The study sponsor is University Hospital, Bonn, a hospital or academic medical center.
Did this study involve medication?
Yes. The study involved medication, including ketamine and Nacl 0.9%.
Who was this study for?
This study was for healthy volunteers. Listed age limits: 18 years to 35 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit meExplore related studies
Other studies that may be relevant based on condition, country, or study type.
CompletedEUCTR 2008-002247-16
A 24-month, Prospective, Randomized, Active-Controlled, Open-Label, Rater Blinded, Multicenter, International Study of the Prevention of Relapse Comparing Long-Acting Injectable Paliperidone Palmit...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.
CompletedNCT01714713
EVP-6124 (Alpha-7 nAChR) for schizophrenia
This study is completed in the United States, in Australia, in Canada, .... It is testing EVP-6124 (Alpha-7 nAChR) for schizophrenia.
CompletedEUCTR 2004-000751-42
A 26-week, International, Multicenter, Open-label Phase IIIb Study of the Safety and Tolerability of Quetiapine Fumarate (SEROQUEL™) Immediate-release Tablets in Daily Doses of 400 mg to 800 mg in ...
This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.